Nurix Therapeutics, Inc. (NRIX:NASDAQ) closed at $26.02 on October 21, 2026, down 0.31% on the day. The stock trades 7.8% below its 52-week high of $28.23 and 153.1% above its 52-week low of $10.28. Over the past year, it gained 144.8%. Nurix Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since October 21, 2025, NRIX closed higher on 127 days (50%). Its best day was December 8, 2025 (+18.68%) and its worst was December 9, 2025 (-8.94%). The stock moved 10% or more in a single session 4 times. It opened at least 5% above the previous day's high 3 times.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Find more stocks like NRIX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.